Gout Flares With Arhalofenate Vs Allopurinol Examined in Study

This article originally appeared here.
Arhalofenate at an 800mg dosage seems safe and well tolerated
Arhalofenate at an 800mg dosage seems safe and well tolerated

HealthDay News — Arhalofenate (800mg) is safe and significantly decreases gout flares compared to allopurinol (300mg), according to a study published online July 27 in Arthritis & Rheumatology.

Jeffrey Poiley, MD, from Arthritis Associates in Orlando, Florida, and colleagues from the Arhalofenate Flare Study conducted a randomized controlled phase IIb trial in which patients were randomly assigned (2:2:2:2:1) to receive 600 mg of arhalofenate, 800 mg of arhalofenate, 300 mg of allopurinol, 300 mg of allopurinol plus 0.6 mg of colchicine, or placebo once a day. To qualify, patients (239) had had at least three flares of gout during the previous year, had discontinued urate-lowering therapy and colchicine, and had a serum uric acid level of 7.5 to 12 mg/dL.

The researchers observed a 46% decrease in flare incidence in the 800mg arhalofenate group versus the 300mg allopurinol group (P=0.0056); 800mg arhalofenate was also significantly better than placebo (P=0.049). However, 800mg arhalofenate was not significantly different from treatment with 300mg allopurinol plus 0.6mg colchicine (P=0.091). Mean changes in serum uric acid level were −12.5% with 600mg arhalofenate and −16.5% with 800mg arhalofenate (P=0.001 and 0.0001, respectively), compared to −0.9% with placebo. The groups showed no meaningful differences in adverse events between groups, and there were no serious adverse events tied to arhalofenate.

"Arhalofenate is the first urate-lowering antiflare therapy," the authors write.

Several authors disclosed financial ties to CymaBay Therapeutics, which manufactures arhalofenate and funded the study.

Full Text